Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109442 · ClinicalTrials.gov registry record · Phase 1
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
A Phase 1 study, sponsored by Affimed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT05109442: Clinical Trial Phase 1 study, sponsored by Affimed.
NCT05109442 is a Phase 1 study that was terminated before completion, run by Affimed. The registered enrollment target is 112 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05109442, a Phase 1 study, was terminated before completion, sponsored by Affimed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Primary Outcome
The number of patients with dose limiting toxicities (DLTs) in the first cycle, as assessed by the National Cancer Institute Common Technology Criteria for Adverse Events (CTCAE) v5.0
Interventions
- DRUG AFM24
- DRUG Atezolizumab 840 MG in 14 ML Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-11-19 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 1 |
Why NCT05109442 stopped before completion
NCT05109442 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which AFM24 is the first listed.
NCT05109442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05109442 about?
NCT05109442 is a clinical study titled "Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers". AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therap...
What is the current status of trial NCT05109442?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2021-11-19. Estimated completion is 2025-06-11.
What interventions are being tested in trial NCT05109442?
The interventions under investigation include: AFM24 (DRUG), Atezolizumab 840 MG in 14 ML Injection (DRUG).
Who is sponsoring clinical trial NCT05109442?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05109442's enrollment target sits among peer trials
112 508th of 2000 higher than 1,489 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI